New drug combo targets Hard-to-Treat cancers with MTAP deletion
NCT ID NCT06188702
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new oral drug called S095035, alone or combined with another drug (TNG462), in 60 adults with advanced solid tumors that have a specific genetic deletion (MTAP). These cancers have not responded to at least one prior treatment. The study aims to check safety, tolerability, and whether the drugs can shrink tumors. It is currently active but not recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
S095035 (MAT2A inhibitor) and TNG462 (PRMT5 inhibitor)
What this could lead to
If successful, this could lead to a new treatment option for people with certain advanced solid tumors that have a specific genetic deletion (MTAP) and have stopped responding to other therapies.
What could go wrong
This is an early (Phase 1/2) and small trial (60 people), so the drug may not work or could cause serious side effects. It is only for tumors with a specific genetic change, limiting who can benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Aichi, 4648681, Japan
-
Centre Georges-François Leclerc
Dijon, 21079, France
-
Community Health Network
Indianapolis, Indiana, 46250, United States
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Hôpital de la Timone (Marseille)
Marseille, 13385, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Gustave Roussy
Paris, 94805, France
-
Instituto Clinico Humanitas Irccs
Rozzano, 20098, Italy
-
Istituto Europeo Di Oncologia
Milan, 20141, Italy
-
Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute
Lake Mary, Florida, 32746, United States
-
NEXT Oncology
Austin, Texas, 78758, United States
-
National Hospital Organization Shikoku Cancer Center
Ehime, 7910280, Japan
-
Policlinico G.B. Rossi A.O.U.I. Di Verona
Verona, 37134, Italy
-
Royal Hobart Hospital
Hobart, 7000, Australia
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Scientia Clinical Research
Randwick, New South Wales, 2031, Australia
-
Start Madrid Group - Hm Ciocc
Madrid, 28050, Spain
-
Taylor Cancer Research Center
Maumee, Ohio, 43537, United States
-
The Alfred
Prahran, Victoria, 3004, Australia
-
The Cancer Institute Hospital of JFCR
Tokyo, 1358550, Japan
-
Townsville University Hospital
Douglas, 4812, Australia
-
Universitätsklinikum Ulm
Ulm, 89081, Germany